…
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | 2152.00M | 1910.00M | 1628.00M | 1618.00M | 1636.00M |
| Minority interest | -13.00M | -33.00M | -62.00M | - | -49.00M |
| Net income | 1667.00M | 1442.00M | 1049.00M | 1060.00M | 1390.00M |
| Selling general administrative | 4364.00M | 4452.00M | 2265.00M | 4483.00M | 4086.00M |
| Selling and marketing expenses | - | - | 2023.00M | - | - |
| Gross profit | 7144.00M | 6824.00M | 6747.00M | 6577.00M | 5950.00M |
| Reconciled depreciation | 360.00M | 324.00M | 309.00M | - | 268.00M |
| Ebit | 2475.00M | 2487.00M | 2483.00M | 1825.00M | 1638.00M |
| Ebitda | 2835.00M | 2683.00M | 2674.00M | 2163.00M | 1951.00M |
| Depreciation and amortization | 360.00M | 196.00M | 191.00M | 338.00M | 313.00M |
| Operating income | 2475.00M | 2206.00M | 1996.00M | 1825.00M | 1638.00M |
| Other operating expenses | 8555.00M | 9027.00M | 9306.00M | 9033.00M | 7907.00M |
| Interest expense | 340.00M | 404.00M | 414.00M | 258.00M | 12.00M |
| Tax provision | 472.00M | 435.00M | 517.00M | 499.00M | 197.00M |
| Interest income | 57.00M | 65.00M | 34.00M | 5.00M | 34.00M |
| Net interest income | -305.00M | -339.00M | -368.00M | - | -2.00M |
| Income tax expense | 472.00M | 435.00M | 517.00M | 499.00M | 197.00M |
| Total revenue | 11030.00M | 11233.00M | 11302.00M | 10858.00M | 9545.00M |
| Total operating expenses | 4669.00M | 4618.00M | 4751.00M | 4752.00M | 4312.00M |
| Cost of revenue | 3886.00M | 4409.00M | 4555.00M | 4281.00M | 3595.00M |
| Total other income expense net | -323.00M | -296.00M | -368.00M | -207.00M | -2.00M |
| Net income from continuing ops | 1680.00M | 1475.00M | 1111.00M | - | 1439.00M |
| Net income applicable to common shares | - | - | - | 1060.00M | 1390.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 32630.00M | 34315.00M | 34055.00M | 34815.00M | 34451.00M |
| Intangible assets | 17486.00M | 18009.00M | 18538.00M | 20040.00M | 18949.00M |
| Other current assets | 78.00M | 429.00M | 1014.00M | - | 61.00M |
| Total liab | 16146.00M | 18091.00M | 17326.00M | 18358.00M | 7971.00M |
| Total stockholder equity | 16425.00M | 16166.00M | 16606.00M | 16331.00M | 26355.00M |
| Other current liab | 367.00M | 2066.00M | 1820.00M | 312.00M | 1954.00M |
| Common stock | 90.00M | 91.00M | 92.00M | 92.00M | 1.00M |
| Capital stock | 90.00M | 91.00M | 92.00M | - | 1.00M |
| Retained earnings | 16160.00M | 27272.00M | 27474.00M | 26730.00M | 37986.00M |
| Good will | 8127.00M | 8202.00M | 8317.00M | 8396.00M | 8246.00M |
| Cash | 1324.00M | 2195.00M | 1044.00M | 684.00M | 414.00M |
| Total current liabilities | 4933.00M | 5812.00M | 4640.00M | 4370.00M | 4238.00M |
| Current deferred revenue | - | - | 21.00M | - | 11.00M |
| Net debt | 7285.00M | 7907.00M | 8412.00M | 9756.00M | 577.00M |
| Short term debt | 836.00M | 1487.00M | 656.00M | 437.00M | 904.00M |
| Short long term debt | 788.00M | 1437.00M | 656.00M | - | 874.00M |
| Short long term debt total | 8609.00M | 10102.00M | 9456.00M | 10440.00M | 991.00M |
| Other stockholder equity | -161.00M | -115.00M | -10960.00M | -10491.00M | - |
| Total current assets | 4550.00M | 5718.00M | 4818.00M | 4059.00M | 5251.00M |
| Short term investments | - | - | -36.00M | - | 1.00M |
| Net receivables | 2123.00M | 1904.00M | 1352.00M | - | 3825.00M |
| Long term debt | 7663.00M | 8542.00M | 8800.00M | - | - |
| Inventory | 1025.00M | 1190.00M | 1408.00M | 1348.00M | 951.00M |
| Accounts payable | 3730.00M | 1973.00M | 1855.00M | 3621.00M | 1369.00M |
| Accumulated other comprehensive income | 336.00M | -11081.00M | -10960.00M | - | -11632.00M |
| Non currrent assets other | 105.00M | 107.00M | 150.00M | 132.00M | 8.00M |
| Non current assets total | 28080.00M | 28597.00M | 29237.00M | 30756.00M | 29200.00M |
| Capital lease obligations | 133.00M | 123.00M | 137.00M | - | 117.00M |
| Breakdown | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -6.00M | 528.00M | -134.00M | - | -33.00M |
| Total cashflows from investing activities | -580.00M | 528.00M | -134.00M | - | - |
| Net borrowings | -1306.00M | 652.00M | -553.00M | - | - |
| Total cash from financing activities | -2612.00M | -1537.00M | -1568.00M | 6911.00M | -1236.00M |
| Net income | 1667.00M | 1475.00M | 1111.00M | 1119.00M | 1439.00M |
| Change in cash | -926.00M | 1213.00M | 383.00M | 205.00M | 82.00M |
| Begin period cash flow | 2250.00M | 994.00M | 611.00M | 406.00M | 323.00M |
| End period cash flow | 1324.00M | 2207.00M | 994.00M | 611.00M | 405.00M |
| Total cash from operating activities | 2337.00M | 2301.00M | 2100.00M | 2063.00M | 1356.00M |
| Depreciation | 360.00M | 324.00M | 309.00M | 287.00M | 268.00M |
| Other cashflows from investing activities | - | 332.00M | 171.00M | - | - |
| Dividends paid | 612.00M | 570.00M | 388.00M | 2682.00M | 1148.00M |
| Change to inventory | 133.00M | 216.00M | -131.00M | -292.00M | -17.00M |
| Change to account receivables | -65.00M | -312.00M | 38.00M | - | 14.00M |
| Sale purchase of stock | -654.00M | -619.00M | -38.00M | - | - |
| Other cashflows from financing activities | -40.00M | -1000.00M | -589.00M | 11111.00M | -88.00M |
| Capital expenditures | 322.00M | 318.00M | 336.00M | 328.00M | 298.00M |
| Change in working capital | 256.00M | 206.00M | -107.00M | 181.00M | -152.00M |
| Stock based compensation | 86.00M | 102.00M | 88.00M | - | -376.00M |
| Other non cash items | 54.00M | 194.00M | 699.00M | 476.00M | -20.00M |
| Free cash flow | 2015.00M | 1983.00M | 1764.00M | 1735.00M | 1058.00M |
Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic
|
Stock Name
|
Change
(GBX) |
Price
(GBX) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to Revenue (x) |
Enterprise Value
to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HLN Haleon PLC |
-4.20 1.10% |
376.00 | 20.24 | 18.94 | 2.95 | 2.02 | 3.68 | 14.19 |
| HIK Hikma Pharmaceuticals PLC |
4.00 0.24% |
1704.00 | 9.73 | 9.03 | 0.85 | 1.45 | 1.53 | 6.07 |
| HCM HUTCHMED China Ltd |
-2.00 0.95% |
208.00 | 5.38 | 19.30 | 3.37 | 2.02 | 2.25 | 2.40 |
| AGY Allergy Therapeutics |
- -% |
4.25 | - | 106.38 | 11.72 | 159.47 | 12.12 | -4.15 |
| STX Shield Therapeutics plc |
-0.17 3.09% |
5.33 | - | 65.36 | 2.24 | 76.33 | 3.34 | -1.49 |
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, and Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands. It also provides various over-the-counter products comprising nasal drops, and cold, flu, and allergy relief products under Theraflu, and Flonase brands for respiratory issues; and pain relief products under Voltaren, Panadol, and Advil brands; and antacids and antihistamine products under TUMS, ENO, and Fenistil brands for digestive health and other issues. Haleon plc was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022. The company was founded in 1715 and is headquartered in Weybridge, the United Kingdom.
| Name | Title | Year Born |
|---|---|---|
| Mr. Brian McNamara | CEO & Exec. Director | 1967 |
| Mr. Tobias Hestler | CFO & Exec. Director | 1972 |
| Ms. Amy Landucci | Head of Digital and Technology | NA |
| Mr. Bjarne Philip Tellmann | Gen. Counsel | 1967 |
| Ms. Tamara Rogers | Chief Marketing Officer | 1969 |
| Ms. Mairead Nayager | Chief HR Officer | 1975 |
| Mr. Bart Derde | Head of Quality and Supply Chain | 1969 |
| Mr. Filippo Lanzi | Head of EMEA & LatAm | NA |
| Ms. Teri Lyng | Head of Transformation & Sustainability | 1962 |
| Ms. Jooyong Lee | Head of Strategy and Office of the CEO | 1977 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.